Brooks O'Neil
Stock Analyst at Lake Street
(1.29)
# 3,389
Out of 4,734 analysts
30
Total ratings
40%
Success rate
-12.05%
Average return
Main Sectors:
Stocks Rated by Brooks O'Neil
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
MODV ModivCare | Maintains: Buy | $30 → $10 | $5.94 | +68.35% | 3 | Jan 13, 2025 | |
RCEL AVITA Medical | Maintains: Buy | $20 → $14 | $8.73 | +60.37% | 6 | Jan 8, 2025 | |
LFVN LifeVantage | Initiates: Buy | $26 | $24.93 | +4.29% | 1 | Dec 19, 2024 | |
LFMD LifeMD | Initiates: Buy | $12 | $5.17 | +132.11% | 1 | Dec 10, 2024 | |
HROW Harrow | Maintains: Buy | $45 → $55 | $36.10 | +52.35% | 3 | Oct 4, 2024 | |
ATEC Alphatec Holdings | Maintains: Buy | $32 → $18 | $11.61 | +55.04% | 4 | Sep 3, 2024 | |
ORGO Organogenesis Holdings | Initiates: Buy | $5 | $3.53 | +41.64% | 1 | Jun 28, 2024 | |
SRDX Surmodics | Downgrades: Hold | $43 | $37.50 | +14.67% | 3 | May 29, 2024 | |
TNDM Tandem Diabetes Care | Maintains: Buy | $60 → $75 | $35.30 | +112.46% | 1 | May 22, 2024 | |
PIII P3 Health Partners | Maintains: Buy | $9 → $4.5 | $0.20 | +2,173.88% | 1 | Mar 14, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $9.14 | +31.29% | 1 | Mar 7, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $75 | $99.65 | -24.74% | 1 | Aug 2, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $26 | $33.90 | -23.30% | 2 | Feb 15, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $45 | $3.88 | +1,059.79% | 1 | Nov 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $1.19 | +824.37% | 1 | Apr 8, 2022 |
ModivCare
Jan 13, 2025
Maintains: Buy
Price Target: $30 → $10
Current: $5.94
Upside: +68.35%
AVITA Medical
Jan 8, 2025
Maintains: Buy
Price Target: $20 → $14
Current: $8.73
Upside: +60.37%
LifeVantage
Dec 19, 2024
Initiates: Buy
Price Target: $26
Current: $24.93
Upside: +4.29%
LifeMD
Dec 10, 2024
Initiates: Buy
Price Target: $12
Current: $5.17
Upside: +132.11%
Harrow
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $55
Current: $36.10
Upside: +52.35%
Alphatec Holdings
Sep 3, 2024
Maintains: Buy
Price Target: $32 → $18
Current: $11.61
Upside: +55.04%
Organogenesis Holdings
Jun 28, 2024
Initiates: Buy
Price Target: $5
Current: $3.53
Upside: +41.64%
Surmodics
May 29, 2024
Downgrades: Hold
Price Target: $43
Current: $37.50
Upside: +14.67%
Tandem Diabetes Care
May 22, 2024
Maintains: Buy
Price Target: $60 → $75
Current: $35.30
Upside: +112.46%
P3 Health Partners
Mar 14, 2024
Maintains: Buy
Price Target: $9 → $4.5
Current: $0.20
Upside: +2,173.88%
Mar 7, 2024
Initiates: Buy
Price Target: $12
Current: $9.14
Upside: +31.29%
Aug 2, 2023
Maintains: Buy
Price Target: $65 → $75
Current: $99.65
Upside: -24.74%
Feb 15, 2023
Maintains: Buy
Price Target: $20 → $26
Current: $33.90
Upside: -23.30%
Nov 21, 2022
Assumes: Buy
Price Target: $45
Current: $3.88
Upside: +1,059.79%
Apr 8, 2022
Initiates: Buy
Price Target: $11
Current: $1.19
Upside: +824.37%